title: FDG PET/CT imaging as a biomarker in lymphoma.
abstract: FDG PET/CT has changed the management of FDG-avid lymphoma and is now recommended as the imaging technique of choice for staging and restaging. The need for tailoring therapy to reduce toxicity in patients with a favourable outcome and for improving treatment in those with high-risk factors requires accurate diagnostic methods and a new prognostic algorithm to identify different risk categories. New drugs are used in relapsed/refractory patients. The role of FDG PET/CT as a biomarker in this context is summarized in this review. New trends in FDG metabolic imaging in lymphoma are addressed including metabolic tumour volume measurement at staging and integrative PET which combines PET data with clinical and molecular markers or other imaging techniques. The quantitative approach for response assessment which is under investigation and is used in large ongoing trials is compared with visual criteria. The place of FDG in the era of targeted therapy is discussed.
authors.affiliation: LYSA Imaging, Department of Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Paris-Est Créteil University, Créteil, 94010, France, michel.meignan@hmn.aphp.fr.
authors.forename: Michel
authors.initials: M
authors.lastname: Meignan
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Itti
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Anas
authors.initials: A
authors.lastname: Younes
mesh_terms: D000818:Animals; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D008223:Lymphoma / Q000000981:diagnostic imaging* / Q000473:pathology; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18